Kamada targets higher CYTOGAM use as post-marketing studies expand in lung transplant CMV prophylaxis

• Kamada plans to expand post-marketing research to build evidence supporting increased CYTOGAM utilization in solid organ transplantation.
• The program targets CMV management in high-risk transplant patients, with a focus on outcomes beyond viral suppression, including immune modulation.
• Management expects additional study readouts later in 2026, with full results from the latest investigator-initiated work slated for publication this year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kamada Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-077360), on July 13, 2026, and is solely responsible for the information contained therein.